Review

human malignant melanoma cell line a375 (ATCC)

ATCC is a verified supplier

ATCC manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ATCC human malignant melanoma cell line a375
Human Malignant Melanoma Cell Line A375, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 5195 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+malignant+melanoma+cell+line+a375/A-375/pmc13088348-209-33-63
Average 99 stars, based on 5195 article reviews

human malignant melanoma cell line a375 - by Bioz Stars, 2026-09

99/100 stars

Images

Cell Culture:

Article Title: Design of human lactoferricin derived antitumor peptides-activity and specificity against malignant melanoma in 2D and 3D model studies.
Article Snippet: .. Human malignant melanoma cell line A375 was purchased from ATCC (American Type Culture Collection, Manassas, Virginia, US) and cultured in Dulbecco’s Modified Eagle Medium DMEM with GlutaMAX TM (Gibco®, Thermo Fisher Scientific, USA) supplemented with 10% fetal bovine serum FBS (Gibco®). .. Further melanoma cell lines from primary lesions SBcl2 and from metastatic lesions WM164 (kindly provided by Dr. Meenhard Herlyn, the Wistar Institute, Philadelphia, PA) were cultured in RPMI 1640 medium with GlutaMAX TM (Gibco®, Thermo Fisher Scientific, USA) supplemented with 2% or 10% FBS, respectively.

Article Title: A novel topoisomerase I inhibitor DIA-001 induces DNA damage mediated cell cycle arrest and apoptosis in cancer cell
Article Snippet: .. Cell culture and antibodies The breast epithelial cell line MCF-10A, mouse muscle myoblast cell line C2C12, human glioma cell lines U251, T98G, LN18, human ovarian cancer cell line OVCAR8, human osteosarcoma cell lines U2OS, human hepatocellular carcinoma cell line HepG2 and human malignant melanoma cell line A375 were purchased from American Type Culture Collection (ATCC, USA). ..

Modification:

Multiple Displacement Amplification:

Article Title: ZBTB21 Is a Dual Suppressor of Pyroptosis and MHC‐I Antigen Presentation That Promotes Tumor Immune Evasion
Article Snippet: .. Mouse triple‐negative breast cancer cell line 4T1 (Cat# CRL‐2539), mouse melanoma cell line B16F10 (Cat# CRL‐6475), mouse hepatocellular carcinoma cell line Hepa1‐6 (Cat# CRL‐1830), human triple‐negative breast cancer cell line MDA‐MB‐231 (Cat# CRM‐HTB‐26), human malignant melanoma cell line A375 (Cat# CRL‐1619), human non‐small cell lung cancer cell line H1299 (Cat# CRL‐5803), and human embryonic kidney 293T (Cat# CRL‐3216) cells were obtained from the American Type Culture Collection. .. All cell lines were maintained in DMEM (Gibco, Cat#C11995500BT) or 1640 (Gibco, Cat#C11875500BT) supplemented with 10% fetal bovine serum (Transgen, Cat#FS301‐02), 100 U/mL penicillin, and 100 μg/mL streptomycin (Transgen, Cat#FG101‐01).

In Vitro:

Article Title: <i>Galium verum L.</i> petroleum ether extract – antitumor potential on human melanoma cells
Article Snippet: Phosphate-buffered saline (PBS), trypsin-EDTA solution, and the in vitro solvent dimethyl sulfoxide (DMSO) were procured from SigmaAldrich (Darmstadt, Germany), MTT viability kit (3- (4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide) from Roche Holding (Basel, Switzerland), and, respectively, Hoechst 33342 staining dye solution from Thermo Fisher Scientific, Inc., Waltham, MA, United States. .. The in vitro evaluations were accomplished on human keratinocyte cell line - HaCaT, (CVCL_0038, CLS, Eppelheim, Germany) and human malignant melanoma cell line - A375 (CRL-1619TM, ATCC®, Manassas, Virginia, USA). ..

Image Search Results

Identification of a circANKRD52 in melanoma cells. (A) The genomic loci of circANKRD52. (B) RT‐qPCR analysis of the expression levels of circANKRD52 and ANKRD52 after treatment with RNase R in A375 and SK‐MEL‐28 cells. (C) RT‐qPCR analysis of the transcriptional stability of circANKRD52 and ANKRD52 after treatment with Actinomycin D in A375 cells. (D) RT‐qPCR analysis of the location of circANKRD52 in A375 and SK‐MEL‐28 cells. (E) FISH analysis of the location of circANKRD52 in A375 and SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. **** p < 0.0001.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CircANKRD52 Augments the Growth and Invasion of Melanoma Cells by Sponging miR ‐141‐3p and Upregulating PRKACB

doi: 10.1111/jcmm.70909

Figure Lengend Snippet: Identification of a circANKRD52 in melanoma cells. (A) The genomic loci of circANKRD52. (B) RT‐qPCR analysis of the expression levels of circANKRD52 and ANKRD52 after treatment with RNase R in A375 and SK‐MEL‐28 cells. (C) RT‐qPCR analysis of the transcriptional stability of circANKRD52 and ANKRD52 after treatment with Actinomycin D in A375 cells. (D) RT‐qPCR analysis of the location of circANKRD52 in A375 and SK‐MEL‐28 cells. (E) FISH analysis of the location of circANKRD52 in A375 and SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. **** p < 0.0001.

Article Snippet: Human malignant melanoma cell lines A375, Hs294T, SK‐MEL‐28 were procured from American Type Culture Collection (ATCC, Manassas, VA, USA) and melanocytes were used as the control cells.

Techniques: Quantitative RT-PCR, Expressing

CircANKRD52 augments proliferation and invasion of melanoma cells. (A) EdU analysis of the cell proliferation activity after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (B) Transwell analysis of the cell invasion capabilities after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (C) Flow cytometry analysis of the cell apoptosis after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (D) Tube formation assay analysis of the angiogenesis ability after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (E) Western blot analysis of the protein levels of VEGF after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. * p < 0.05.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CircANKRD52 Augments the Growth and Invasion of Melanoma Cells by Sponging miR ‐141‐3p and Upregulating PRKACB

doi: 10.1111/jcmm.70909

Figure Lengend Snippet: CircANKRD52 augments proliferation and invasion of melanoma cells. (A) EdU analysis of the cell proliferation activity after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (B) Transwell analysis of the cell invasion capabilities after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (C) Flow cytometry analysis of the cell apoptosis after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (D) Tube formation assay analysis of the angiogenesis ability after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (E) Western blot analysis of the protein levels of VEGF after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. * p < 0.05.

Techniques: Activity Assay, Transfection, Flow Cytometry, Tube Formation Assay, Western Blot

The circANKRD52 acts as a sponge of miR‐141‐3p in melanoma cells. (A) The RNA pull‐down analysis of the binding between circANKRD52 probe and miRNA in A375 cells. (B) RT‐qPCR analysis of the expression levels of miR‐141‐3p in melanoma and the adjacent normal tissues. (C) Pearson's correlation analysis of the correlation between miR‐141‐3p and circANKRD52 in melanoma tissues. (D) RT‐qPCR analysis of the expression of miR‐141‐3p in melanoma cell lines (A375, Hs294T, and SK‐MEL‐28). (E) The dual luciferase reporter assay indicated the binding between circANKRD52 3′UTR and miR‐141‐3p. (F) RT‐qPCR analysis of the expression of miR‐141‐3p after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (G) RIP analysis of the binding ability between circANKRD52 and Ago2 after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (H) RNA pull‐down assay analysis of the binding between Bio‐circANKRD52 WT and miR‐141‐3p. Data shown are the mean ± SEM of three experiments. * p < 0.05.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CircANKRD52 Augments the Growth and Invasion of Melanoma Cells by Sponging miR ‐141‐3p and Upregulating PRKACB

doi: 10.1111/jcmm.70909

Figure Lengend Snippet: The circANKRD52 acts as a sponge of miR‐141‐3p in melanoma cells. (A) The RNA pull‐down analysis of the binding between circANKRD52 probe and miRNA in A375 cells. (B) RT‐qPCR analysis of the expression levels of miR‐141‐3p in melanoma and the adjacent normal tissues. (C) Pearson's correlation analysis of the correlation between miR‐141‐3p and circANKRD52 in melanoma tissues. (D) RT‐qPCR analysis of the expression of miR‐141‐3p in melanoma cell lines (A375, Hs294T, and SK‐MEL‐28). (E) The dual luciferase reporter assay indicated the binding between circANKRD52 3′UTR and miR‐141‐3p. (F) RT‐qPCR analysis of the expression of miR‐141‐3p after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (G) RIP analysis of the binding ability between circANKRD52 and Ago2 after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (H) RNA pull‐down assay analysis of the binding between Bio‐circANKRD52 WT and miR‐141‐3p. Data shown are the mean ± SEM of three experiments. * p < 0.05.

Techniques: Binding Assay, Quantitative RT-PCR, Expressing, Luciferase, Reporter Assay, Transfection, Pull Down Assay

The miR‐141‐3p reverses circANKRD52‐induced melanoma cell proliferation and invasion. (A) EdU analysis of the cell proliferation activity after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. (B) Transwell analysis of the cell invasion capabilities after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. (C) Flow cytometry analysis of the cell apoptosis after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. (D) Tube formation assay analysis of the angiogenesis ability after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. (E) Western blot analysis of the protein levels of VEGF after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. * p < 0.05.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CircANKRD52 Augments the Growth and Invasion of Melanoma Cells by Sponging miR ‐141‐3p and Upregulating PRKACB

doi: 10.1111/jcmm.70909

Figure Lengend Snippet: The miR‐141‐3p reverses circANKRD52‐induced melanoma cell proliferation and invasion. (A) EdU analysis of the cell proliferation activity after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. (B) Transwell analysis of the cell invasion capabilities after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. (C) Flow cytometry analysis of the cell apoptosis after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. (D) Tube formation assay analysis of the angiogenesis ability after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. (E) Western blot analysis of the protein levels of VEGF after co‐transfection with oe‐circANKRD52 and miR‐141‐3p mimic into A375 cells or sh‐circANKRD52 and miR‐141‐3p inhibitor into SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. * p < 0.05.

Techniques: Activity Assay, Cotransfection, Flow Cytometry, Tube Formation Assay, Western Blot

PRKACB is identified as a direct target of miR‐141‐3p in melanoma cells. (A) RT‐qPCR analysis of the PRKACB expression in melanoma and the adjacent normal tissues. (B) Pearson's correlation analysis of the correlations of PRKACB with miR‐141‐3p or circANKRD52 expression in melanoma tissues. (C, D) RT‐qPCR and Western blot analysis of the expression of PRKACB in A375, SK‐MEL‐28, and melanocytes. (E) The dual luciferase reporter assay indicated the binding between miR‐141‐3p and PRKACB 3'UTR. (F) RT‐qPCR analysis of the expression of PRKACB after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (G) RT‐qPCR analysis of the expression of PRKACB after transfection with miR‐141‐3p mimic into A375 cells or miR‐141‐3p inhibitor into SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. * p < 0.05. # p < 0.05.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CircANKRD52 Augments the Growth and Invasion of Melanoma Cells by Sponging miR ‐141‐3p and Upregulating PRKACB

doi: 10.1111/jcmm.70909

Figure Lengend Snippet: PRKACB is identified as a direct target of miR‐141‐3p in melanoma cells. (A) RT‐qPCR analysis of the PRKACB expression in melanoma and the adjacent normal tissues. (B) Pearson's correlation analysis of the correlations of PRKACB with miR‐141‐3p or circANKRD52 expression in melanoma tissues. (C, D) RT‐qPCR and Western blot analysis of the expression of PRKACB in A375, SK‐MEL‐28, and melanocytes. (E) The dual luciferase reporter assay indicated the binding between miR‐141‐3p and PRKACB 3'UTR. (F) RT‐qPCR analysis of the expression of PRKACB after transfection with oe‐circANKRD52 into A375 cells or sh‐circANKRD52 into SK‐MEL‐28 cells. (G) RT‐qPCR analysis of the expression of PRKACB after transfection with miR‐141‐3p mimic into A375 cells or miR‐141‐3p inhibitor into SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. * p < 0.05. # p < 0.05.

Techniques: Quantitative RT-PCR, Expressing, Western Blot, Luciferase, Reporter Assay, Binding Assay, Transfection

The circANKRD52/PRKACB axis mediates melanoma cell proliferation and invasion. (A) EdU analysis of the cell proliferation activity after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. (B) Transwell analysis of the cell invasion capabilities after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. (C) Flow cytometry analysis of the cell apoptosis after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. (D) Tube formation assay analysis of the angiogenesis ability after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. (E) Western blot analysis of the protein levels of VEGF after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. * p < 0.05.

Journal: Journal of Cellular and Molecular Medicine

Article Title: CircANKRD52 Augments the Growth and Invasion of Melanoma Cells by Sponging miR ‐141‐3p and Upregulating PRKACB

doi: 10.1111/jcmm.70909

Figure Lengend Snippet: The circANKRD52/PRKACB axis mediates melanoma cell proliferation and invasion. (A) EdU analysis of the cell proliferation activity after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. (B) Transwell analysis of the cell invasion capabilities after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. (C) Flow cytometry analysis of the cell apoptosis after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. (D) Tube formation assay analysis of the angiogenesis ability after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. (E) Western blot analysis of the protein levels of VEGF after co‐transfection with oe‐circANKRD52 and sh‐PRKACB into A375 cells or sh‐circANKRD52 and oe‐PRKACB into SK‐MEL‐28 cells. Data shown are the mean ± SEM of three experiments. * p < 0.05.

Techniques: Activity Assay, Cotransfection, Flow Cytometry, Tube Formation Assay, Western Blot

Review

human malignant melanoma cell line a375 (ATCC)

Structured Review

Images

Related Articles

Cell Culture:

Modification:

Multiple Displacement Amplification:

In Vitro:

Similar Products

Image Search Results